Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Conclusion: PTLD is a heterogeneous group of immunodeficiency-associated lymphoproliferative disorders. The overall survival in non-destructive, polymorphic, and monomorphic PTLD were similar. Monomorphic T/NK cell types had inferior outcomes.Figure.DisclosuresMaurer: Morphosys: Research Funding; Nanostring: Research Funding; Celgene: Research Funding. Ansell: Celldex: Research Funding; Merck & Co: Research Funding; Takeda: Research Funding; LAM Therapeutics: Research Funding; Seattle Genetics: Research Funding; Trillium: Research Funding; Bristol-Myers Squibb: Research Funding; Affimed: Research Funding; Regeneron: Research Funding; Pfizer: Research Funding. Cerhan: Celgene: Research Funding; Nanostring: Research Funding; Jannsen: Other: Scientific Advisory Board.

Source: Blood - November 21, 2018 Category: Hematology Authors: Habermann, T. M., Fama, A., Ristow, K. M., Maurer, M. J., Macon, W. R., Ansell, S. M., Bennani, N. N., Kudva, Y. C., Walker, R. C., Watt, K. D., Schwab, T. R., Cerhan, J. R., King, R. L. Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma Source Type: research